KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Convertible Debt (2019 - 2022)

Inovio Pharmaceuticals' Convertible Debt history spans 4 years, with the latest figure at $16.6 million for Q4 2022.

  • For Q4 2022, Convertible Debt rose 11.06% year-over-year to $16.6 million; the TTM value through Dec 2022 reached $16.6 million, up 11.06%, while the annual FY2022 figure was $16.6 million, 11.06% up from the prior year.
  • Convertible Debt for Q4 2022 was $16.6 million at Inovio Pharmaceuticals, up from $16.3 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $64.2 million in Q4 2019 and bottomed at $4.2 million in Q3 2020.
  • The 4-year median for Convertible Debt is $14.5 million (2020), against an average of $17.6 million.
  • The largest annual shift saw Convertible Debt crashed 77.97% in 2020 before it rose 15.2% in 2022.
  • A 4-year view of Convertible Debt shows it stood at $64.2 million in 2019, then plummeted by 77.97% to $14.1 million in 2020, then grew by 5.8% to $15.0 million in 2021, then rose by 11.06% to $16.6 million in 2022.
  • Per Business Quant, the three most recent readings for INO's Convertible Debt are $16.6 million (Q4 2022), $16.3 million (Q3 2022), and $16.5 million (Q2 2022).